- Eisai and Biogen posted promising data for BAN2401 that lifted its stock and had the pharma trade publications talking breakthrough.
- But there is a lot of controversy swirling around the study.
- It seems that Biogen may have moved the goal posts to gain more favorable data endpoints.
- It’s not about patients, it’s about the stock price and getting investors on board.
KEY TAKEAWAY: When a CEO decides to take the money and leave a company facing challenges you have to wonder why in the hell he was eve named CEO? Continue reading
KEY TAKEAWAY: Spending $40 million on a DTC campaign to increase awareness of a drug that people are demolishing on social media is a waste of money. Surely DTC marketers can do better than this. Continue reading
KEY TAKEAWAY: Small biotech companies should use what is happening to Biogen as a lesson in what not to as they deal with growth and success, but it’s sure to happen again and again as Pharma seems reluctant to learn business lessons. Continue reading